The standard of care for advanced prostate cancer (PCa) consists of Androgen Deprivation Therapy (ADT) and the use of ever more effective therapies targeting the androgen receptor (AR) under different mechanisms (reviewed in [1]). This evidence concerns the gene AR and prostate carcinoma.